The results in the table (Figure 7A) indicate that patients with CYP4B1 gene expression levels showed a significantly (p < 0.05) increased risk of breast cancer in the Lumina B subtype, whereas those patients with CYP4F12 gene expression levels depicted a significantly (p < 0.05) decreased risk of breast cancer in the Luminal A subtype, while CYP4F3 showed no significant difference. This evidence concerns the gene CYP4F12 and breast cancer.